Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Public ClinicalTrials.gov record NCT04975997. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Study identification
- NCT ID
- NCT04975997
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 939 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 23, 2022 (Actual)
- Primary completion
- Nov 16, 2027 (Estimated)
- Completion
- Jun 25, 2032 (Estimated)
- Last update posted
- Apr 3, 2026
2022 – 2032
United States locations
- U.S. sites
- 43
- U.S. states
- 24
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 035 | Hot Springs | Arkansas | 71913 | — |
| Local Institution - 641 | Cerritos | California | 90703-2679 | — |
| Local Institution - 681 | Fountain Valley | California | 92708 | — |
| Local Institution - 047 | Los Angeles | California | 90033 | — |
| Local Institution - 684 | Newport | California | 92663 | — |
| Local Institution - 033 | New Haven | Connecticut | 06511 | — |
| Local Institution - 029 | Fort Myers | Florida | 33901 | — |
| Local Institution - 693 | Ocala | Florida | 34471-6950 | — |
| Local Institution - 028 | St. Petersburg | Florida | 33705 | — |
| Local Institution - 045 | Tamarac | Florida | 33321-2909 | — |
| Local Institution - 034 | West Palm Beach | Florida | 33401 | — |
| Local Institution - 685 | Weston | Florida | 33331-3609 | — |
| Local Institution - 018 | Atlanta | Georgia | 30322 | — |
| Local Institution - 640 | Elk Grove Village | Illinois | 60007-3363 | — |
| Local Institution - 697 | Dyer | Indiana | 46311-1596 | — |
| Local Institution - 040 | Louisville | Kentucky | 40207 | — |
| Local Institution - 041 | Alexandria | Louisiana | 71301-3841 | — |
| Local Institution - 682 | Baton Rouge | Louisiana | 70808-4300 | — |
| Local Institution - 027 | Baton Rouge | Louisiana | 70809-3675 | — |
| Local Institution - 698 | Baltimore | Maryland | 21204-6826 | — |
| Local Institution - 014 | Bethesda | Maryland | 20817 | — |
| Local Institution - 688 | Columbia | Maryland | 21044-3128 | — |
| Local Institution - 010 | Boston | Massachusetts | 02215 | — |
| Local Institution - 009 | Worcester | Massachusetts | 01655 | — |
| Local Institution - 645 | Burnsville | Minnesota | 55337-6749 | — |
| Local Institution - 031 | Kansas City | Missouri | 64132 | — |
| Local Institution - 046 | Billings | Montana | 59102-6746 | — |
| Local Institution - 015 | Summit | New Jersey | 07901 | — |
| Local Institution - 691 | New York | New York | 10016 | — |
| Local Institution - 039 | Durham | North Carolina | 27705 | — |
| Local Institution - 038 | Cincinnati | Ohio | 45220 | — |
| Local Institution - 037 | Cleveland | Ohio | 44109 | — |
| Local Institution - 008 | Cleveland | Ohio | 44195 | — |
| Local Institution - 036 | Columbus | Ohio | 43214 | — |
| Local Institution - 680 | Tulsa | Oklahoma | 74146-6236 | — |
| Local Institution - 043 | Portland | Oregon | 97239 | — |
| Local Institution - 030 | Chattanooga | Tennessee | 37404 | — |
| Local Institution - 021 | Nashville | Tennessee | 37203 | — |
| Local Institution - 687 | Austin | Texas | 78705-1165 | — |
| Local Institution - 695 | Houston | Texas | 77025 | — |
| Local Institution - 642 | Newport News | Virginia | 23606-3069 | — |
| Local Institution - 643 | Roanoke | Virginia | 24014-2419 | — |
| Local Institution - 025 | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 216 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04975997, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04975997 live on ClinicalTrials.gov.